Survival Meta analysis for Entecavir versus Lamivudine therapy for patients with HBV-related liver failure
10.3760/cma.j.issn.1003-9279.2016.04.018
- VernacularTitle:恩替卡韦与拉米夫定治疗乙型肝炎病毒相关肝衰竭生存率Meta分析
- Author:
Hongzhu YIN
1
;
Weiyan YU
;
Caiyan ZHAO
Author Information
1. 河北医科大学第三医院感染科
- Keywords:
Liver failure;
Hepatitis B;
Entecavir;
Lamivudine;
Survival rate;
Meta analysis
- From:
Chinese Journal of Experimental and Clinical Virology
2016;30(4):411-417
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the short-term and long-term survival rate for Entecavir versus Lamivudine in the treatment of patients with HBV-related liver failure through Meta-analysis.Methods Relevant literature published from 2007 to 2015 in Chinese or English were searched,papers fully matching the inclusion criteria were brought into the study.RavMan 5.2 statistical software was utilized for Meta-analysis.The survival rate of 4-week,12-week,24-week,48-week were analyzed by forest plot.Results Total 1837 patients from 18 controlled clinical trials reported in Chinese and English were recruited in this study,which involving survival rate for Entecavir versus Lamivudine in the treatment of patients with HBV-related liver failure.Among them 12 papers were cohort and 6 were RCT(Randomized Controlled Trial) study.Meta analysis show:HBV DNA undetectable rate of 4-week、12-week、24-week and 48-week in Entecavir group were higher than that in Lamivudine group (4-week:RR =1.52,Z =4.11,P ＜ 0.01;12-week:RR =1.26,Z =3.85,P ＜0.01;24-week:RR =1.26,Z =5.16,P ＜0.01;48-week:RR =1.22,Z =3.41,P ＜ 0.01),survival rate of four-week,twelve-week,twenty four-week had no significant differences between Entecavir and Lamivudine group (4-week:RR =0.97,Z =0.55,P =0.58;12-week:RR =1.01,Z =0.15,P =0.88;24-week:RR =1.02,Z =0.56,P =0.57),fourty eight-week survival rate in Entecavir group was higher than that in Lamivudine group(48-week:RR =1.18,Z =2.84,P ＜ 0.01).Conclusions The data indicated that Entecavir was more effective in the management of HBV levels and better improve the long-term prognosis of patients with HBV-associated liver failure than Lamivudine,which might be more suitable for long-term treatment to patients with HBV-related liver failure.
